COPD and vitamin K antagonism: a cohort study of 1-year all-cause mortality and risk of hospitalisation due to a severe exacerbation.

ABSTRACT:

Background

Vitamin K, through its role in the vitamin K-dependent activation of matrix-GLA-protein, has been suggested to have a lung-protective effect, though the mechanism is unknown. Chronic obstructive pulmonary disease (COPD) patients treated with vitamin K antagonists (VKAs) may lose this protection, thereby increasing their risk of an acute exacerbation of COPD (AE-COPD) and death. We examined this hypothesis in a nationwide cohort of COPD patients treated with VKA. COPD patients treated with direct oral anticoagulant (DOAC) served as controls.

Objective

To assess the association between VKA treatment and the 1-year risk of AE-COPD-related hospitalisation and all-cause mortality in patients with COPD and atrial fibrillation or flutter.

Methods

This nationwide,

SUBMITTER: Gundersen BVV 

PROVIDER: S-EPMC12853482 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature